Literature DB >> 10820289

Cytolytic T lymphocytes raised against a human bladder carcinoma recognize an antigen encoded by gene MAGE-A12.

L Heidecker1, F Brasseur, M Probst-Kepper, M Guéguen, T Boon, B J Van den Eynde.   

Abstract

Human bladder carcinoma line LB831-BLC expresses several distinct Ags that are recognized by different autologous CTL. Here, we show that one of these Ags is presented by HLA-Cw7 and encoded by gene MAGE-A12. This is the first time that CTL directed against a MAGE-encoded Ag have been derived from the lymphocytes of a patient with cancer other than melanoma. This new Ag was found to be nonapeptide VRIGHLYIL, corresponding to position 170-178 of the MAGE-A12 protein. Gene MAGE-A12 is silent in normal tissues except in male germline cells, which do not express HLA molecules. It is expressed in 26-62% of melanomas, infiltrating bladder carcinomas, lung carcinomas, esophageal carcinomas, and head and neck carcinomas. Because HLA-Cw7 is present in 43% of Caucasians, this new Ag is shared by many tumors and should be a useful target for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820289     DOI: 10.4049/jimmunol.164.11.6041

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Identification of HLA-Cw6.02 and HLA-Cw7.01 allele-specific binding motifs by screening synthetic peptide libraries.

Authors:  Sara O Dionne; Douglas F Lake; William J Grimes; Margaret H Smith
Journal:  Immunogenetics       Date:  2004-08-12       Impact factor: 2.846

Review 2.  Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

Authors:  Helen Y Wang; Rong-Fu Wang
Journal:  Adv Immunol       Date:  2012       Impact factor: 3.543

3.  An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Authors:  Alexandre Dalet; Paul F Robbins; Vincent Stroobant; Nathalie Vigneron; Yong F Li; Mona El-Gamil; Ken-ichi Hanada; James C Yang; Steven A Rosenberg; Benoît J Van den Eynde
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-13       Impact factor: 11.205

Review 4.  Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Authors:  Adam J Linley; Murrium Ahmad; Robert C Rees
Journal:  Int J Hematol       Date:  2011-03-01       Impact factor: 2.490

Review 5.  Immune targets and neoantigens for cancer immunotherapy and precision medicine.

Authors:  Rong-Fu Wang; Helen Y Wang
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

6.  Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Authors:  Shigui Zhu; Benoit J Van den Eynde; Pierre G Coulie; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

7.  Association of HLA-B*51:01 with papillary thyroid carcinoma in the Chinese Han population of the Shandong coastal areas.

Authors:  Jiao Shuxian; Chi Xiaoyun; Feng Zhihui; Liu Xiaohua; Du Zhanhui; Hu Bin; Zhao Lin
Journal:  Thyroid       Date:  2014-01-30       Impact factor: 6.568

8.  Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.

Authors:  Dominique Chopin; Reza Barei-Moniri; Pascale Maillé; Marie-Aude Le Frère-Belda; Béatrice Muscatelli-Groux; Nicolò Merendino; Laure Lecerf; Antonella Stoppacciaro; Francesca Velotti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

9.  '1-8 interferon inducible gene family': putative colon carcinoma-associated antigens.

Authors:  B Tirosh; V Daniel-Carmi; L Carmon; A Paz; G Lugassy; E Vadai; A Machlenkin; E Bar-Haim; M-S Do; I S Ahn; M Fridkin; E Tzehoval; L Eisenbach
Journal:  Br J Cancer       Date:  2007-12-11       Impact factor: 7.640

10.  MAGE-A8 overexpression in transitional cell carcinoma of the bladder: identification of two tumour-associated antigen peptides.

Authors:  E Bar-Haim; A Paz; A Machlenkin; D Hazzan; B Tirosh; L Carmon; B Brenner; E Vadai; O Mor; A Stein; F A Lemonnier; E Tzehoval; L Eisenbach
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.